Inhalable Biologics Global Market Report 2025

Description

Inhalable biologics are biologic drugs that are delivered through the respiratory tract via inhalation. This method allows for targeted treatment of lung diseases or systemic therapy by directly reaching the lungs, which enhances the drug's effectiveness and minimizes side effects.

The primary types of inhalable biologics include peptides and proteins, vaccines, monoclonal antibodies, RNAi-based therapeutics, and others. Peptide and protein therapeutics are bioactive molecules designed to influence specific cellular pathways or replace deficient proteins. These biologics are available in various dosage forms, such as dry powder inhalers, metered-dose inhalers, nebulizers, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used in the treatment of respiratory diseases, diabetes, cancer, and other conditions.

The inhalable biologics market research report is one of a series of new reports from The Business Research Company that provides inhalable biologics market statistics, including inhalable biologics industry global market size, regional shares, competitors with an inhalable biologics market share, detailed inhalable biologics market segments, market trends and opportunities, and any further data you may need to thrive in the inhalable biologics industry. This inhalable biologic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhalable biologics market size has grown rapidly in recent years. It will grow from $2.79 billion in 2024 to $3.25 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth during the historic period can be attributed to the rising prevalence of respiratory diseases globally, a growing demand for non-invasive delivery methods, increased awareness of the benefits of biologics, and the expanding research and investment in biopharmaceuticals.

The inhalable biologics market size is expected to see rapid growth in the next few years. It will grow to $5.90 billion in 2029 at a compound annual growth rate (CAGR) of 16.0%. The growth during the forecast period can be attributed to the increasing global aging population, the expansion of healthcare infrastructure in emerging markets, growing regulatory support for biologics therapy, and a rise in cases of infectious respiratory diseases. Key trends expected during this period include advancements in drug delivery systems, the integration of smart inhaler technology, innovations in aerosol science, developments in biologic drug formulations, and progress in nanoparticle-based carriers.

The growing prevalence of respiratory disorders is expected to significantly contribute to the growth of the inhalable biologics market in the coming years. Respiratory disorders encompass diseases and conditions affecting the lungs and other components of the respiratory system, including the airways, nasal passages, and lungs. The rise in these conditions is largely attributed to increasing air pollution, which exacerbates ailments such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and pollutants. Inhalable biologics are particularly effective for these conditions as they deliver targeted treatments directly to the lungs, reducing inflammation and improving lung function with fewer systemic side effects. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that in 2023, COPD accounted for 3.6% of the total disease burden and 50% of the respiratory disease burden. Consequently, the rise in respiratory disorders is significantly boosting the inhalable biologics market.

Leading companies in the inhalable biologics market are focusing on developing groundbreaking solutions, such as inhaled insulin, to enhance patient compliance and provide faster glycemic control. Inhaled insulin is a form of insulin that is delivered directly into the bloodstream through the lungs via inhalation, rather than through injections or insulin pumps. This method involves inhaling a powder or aerosolized insulin, which is absorbed through the lungs and quickly enters the bloodstream to regulate blood sugar levels. For example, in February 2025, Cipla Limited, an India-based pharmaceutical company, received regulatory approval from the Central Drugs Standard Control Organization for Afrezza, the world's fastest inhaled insulin, offering a needle-free option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin works within 12 to 15 minutes of inhalation, closely mimicking the natural insulin response to meals and improving blood sugar control. Inhaled insulin presents a more comfortable alternative to daily injections, especially for patients with injection anxiety, enhancing adherence to insulin therapy.

In June 2022, Kindeva Drug Delivery Limited, a US-based pharmaceutical company, acquired iPharma Labs Inc. for an undisclosed amount. This acquisition allows Kindeva to integrate iPharma's expertise in inhalation formulations and early-stage drug development with its global capabilities in developing, commercializing, and manufacturing inhaled therapies. This combination strengthens Kindeva's position, enabling it to offer a more comprehensive, end-to-end solution for the development and manufacturing of respiratory medicines. iPharma Labs is a US-based contract research organization specializing in developing and formulating inhaled therapies, including inhalable biologics.

Major players in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Medtronic PLC, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation.

North America was the largest region in the inhalable biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inhalable biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the inhalable biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The inhalable biologics market consists of sales of inhaled antibodies, inhalable mRNA-based therapeutics, inhaled vaccines, inhaled enzyme replacement therapies, and inhalable gene therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inhalable Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inhalable biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inhalable biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inhalable biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Peptides And Proteins; Vaccines; Monoclonal Antibodies; RNAi-Based Therapeutics; Other Types
2) By Dosage Form: Dry Powder Inhalers; Metered Dose Inhalers; Nebulizers; Other Dosage Forms
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By Application: Respiratory Diseases; Diabetes; Cancer; Other Applications
Subsegments:
1) By Peptides And Proteins: Insulin; Growth Hormones; Enzyme Replacement Therapies; Other Peptides And Proteins
2) By Vaccines: Influenza Vaccines; Other Respiratory Vaccines
3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies; Immunomodulatory Monoclonal Antibodies; Other Monoclonal Antibodies
4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases; Other RNAi-Based Therapeutics
5) By Other Types: Gene Therapies; Small Molecule Inhalable Drugs; Other Innovative Inhalable Biologics
Companies Mentioned: Bayer AG; Sanofi SA; AstraZeneca plc; Novartis AG; GlaxoSmithKline plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r35444

1. Executive Summary

2. Inhalable Biologics Market Characteristics

3. Inhalable Biologics Market Trends And Strategies

4. Inhalable Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Inhalable Biologics Growth Analysis And Strategic Analysis Framework

5.1. Global Inhalable Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Inhalable Biologics Market Growth Rate Analysis
5.4. Global Inhalable Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Inhalable Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Inhalable Biologics Total Addressable Market (TAM)

6. Inhalable Biologics Market Segmentation

6.1. Global Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peptides And Proteins
Vaccines
Monoclonal Antibodies
RNAi-Based Therapeutics
Other Types
6.2. Global Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dry Powder Inhalers
Metered Dose Inhalers
Nebulizers
Other Dosage Forms
6.3. Global Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Inhalable Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Respiratory Diseases
Diabetes
Cancer
Other Applications
6.5. Global Inhalable Biologics Market, Sub-Segmentation Of Peptides And Proteins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Insulin
Growth Hormones
Enzyme Replacement Therapies
Other Peptides And Proteins
6.6. Global Inhalable Biologics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Influenza Vaccines
Other Respiratory Vaccines
6.7. Global Inhalable Biologics Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Respiratory Monoclonal Antibodies
Immunomodulatory Monoclonal Antibodies
Other Monoclonal Antibodies
6.8. Global Inhalable Biologics Market, Sub-Segmentation Of RNAi-Based Therapeutics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
RNA-Based Drugs For Respiratory Diseases
Other RNAi-Based Therapeutics
6.9. Global Inhalable Biologics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gene Therapies
Small Molecule Inhalable Drugs
Other Innovative Inhalable Biologics

7. Inhalable Biologics Market Regional And Country Analysis

7.1. Global Inhalable Biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Inhalable Biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inhalable Biologics Market

8.1. Asia-Pacific Inhalable Biologics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inhalable Biologics Market

9.1. China Inhalable Biologics Market Overview
9.2. China Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inhalable Biologics Market

10.1. India Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inhalable Biologics Market

11.1. Japan Inhalable Biologics Market Overview
11.2. Japan Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inhalable Biologics Market

12.1. Australia Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inhalable Biologics Market

13.1. Indonesia Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inhalable Biologics Market

14.1. South Korea Inhalable Biologics Market Overview
14.2. South Korea Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inhalable Biologics Market

15.1. Western Europe Inhalable Biologics Market Overview
15.2. Western Europe Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inhalable Biologics Market

16.1. UK Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inhalable Biologics Market

17.1. Germany Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inhalable Biologics Market

18.1. France Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inhalable Biologics Market

19.1. Italy Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inhalable Biologics Market

20.1. Spain Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inhalable Biologics Market

21.1. Eastern Europe Inhalable Biologics Market Overview
21.2. Eastern Europe Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inhalable Biologics Market

22.1. Russia Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inhalable Biologics Market

23.1. North America Inhalable Biologics Market Overview
23.2. North America Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inhalable Biologics Market

24.1. USA Inhalable Biologics Market Overview
24.2. USA Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inhalable Biologics Market

25.1. Canada Inhalable Biologics Market Overview
25.2. Canada Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inhalable Biologics Market

26.1. South America Inhalable Biologics Market Overview
26.2. South America Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inhalable Biologics Market

27.1. Brazil Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inhalable Biologics Market

28.1. Middle East Inhalable Biologics Market Overview
28.2. Middle East Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inhalable Biologics Market

29.1. Africa Inhalable Biologics Market Overview
29.2. Africa Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inhalable Biologics Market Competitive Landscape And Company Profiles

30.1. Inhalable Biologics Market Competitive Landscape
30.2. Inhalable Biologics Market Company Profiles
- 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Inhalable Biologics Market Other Major And Innovative Companies

31.1. Medtronic PLC
31.2. Moderna Inc.
31.3. Pfizer Inc. and BioNTech SE
31.4. Teva Pharmaceuticals
31.5. Baxter International
31.6. Lonza Group AG
31.7. CanSino Biologics Inc.
31.8. Cipla Ltd.
31.9. Insmed Incorporated
31.10. Kamada Pharmaceuticals
31.11. Vectura Group plc
31.12. F. Hoffmann-La Roche Ltd
31.13. Iconovo AB
31.14. Synairgen plc
31.15. Ab Initio Pharma LLC

32. Global Inhalable Biologics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inhalable Biologics Market

34. Recent Developments In The Inhalable Biologics Market

35. Inhalable Biologics Market High Potential Countries, Segments and Strategies

35.1 Inhalable Biologics Market In 2029 - Countries Offering Most New Opportunities
35.2 Inhalable Biologics Market In 2029 - Segments Offering Most New Opportunities
35.3 Inhalable Biologics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer